Stoke Therapeutics Inc
STOK25.110USD
+2.740+12.25%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.38B总市值
34.12市盈率 TTM
关于 Stoke Therapeutics Inc 公司
Stoke Therapeutics, Inc. 是一家生物技术公司，致力于通过使用基于核糖核酸 (RNA) 的药物上调蛋白质表达来解决严重疾病的根本原因。该公司通过其专有的靶向增强核基因输出 (TANGO) 方法，致力于开发反义寡核苷酸 (ASO) 以选择性恢复蛋白质水平。其首款化合物 STK-001 正在进行临床试验，用于治疗 Dravet 综合征，这是一种严重的渐进性遗传性癫痫。TANGO 旨在通过增加或刺激健康基因的蛋白质输出来恢复缺失的蛋白质，从而补偿无功能的基因副本。该公司正在开发 STK-002，用于治疗最常见的遗传性视神经疾病常染色体显性视神经萎缩 (ADOA)。该公司的初始重点是单倍体不足以及中枢神经系统和眼睛疾病。
Stoke Therapeutics Inc简介
公司代码STOK
公司名称Stoke Therapeutics Inc
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
员工数量128
证券类型Ordinary Share
年结日Jun 19
公司地址45 Wiggins Avenue
城市BEDFORD
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编01730
电话17814308200
网址https://www.stoketherapeutics.com/
公司代码STOK
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
Stoke Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
49.12K
-46.36%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Mr. Thomas Leggett
Mr. Thomas Leggett
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
49.12K
-46.36%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
13.82M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 10月8日 周三
更新时间: 10月8日 周三
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.42%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.66%
其他
55.38%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.42%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.66%
其他
55.38%
股东类型
持股股东
占比
Investment Advisor
49.19%
Investment Advisor/Hedge Fund
38.56%
Research Firm
14.55%
Hedge Fund
12.80%
Individual Investor
4.21%
Pension Fund
0.20%
Bank and Trust
0.20%
Insurance Company
0.03%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
305
65.94M
115.45%
-1.62M
2025Q2
300
63.05M
115.48%
-5.58M
2025Q1
306
66.97M
122.66%
-2.21M
2024Q4
301
61.22M
115.58%
-8.44M
2024Q3
297
61.15M
115.51%
-9.18M
2024Q2
284
64.23M
122.75%
+5.19M
2024Q1
273
57.18M
122.36%
+3.72M
2023Q4
261
48.04M
104.80%
-6.40M
2023Q3
264
46.81M
105.69%
-6.29M
2023Q2
260
49.41M
111.78%
-2.48M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
5.95M
10.86%
+3.48M
+140.94%
Jun 30, 2025
Lynx1 Capital Advisors LLC
5.40M
9.86%
+112.75K
+2.13%
Jun 30, 2025
RTW Investments L.P.
5.12M
9.35%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
4.63M
8.46%
--
--
Jun 30, 2025
Redmile Group, LLC
4.38M
7.99%
-110.05K
-2.45%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
6.16%
+157.85K
+4.91%
Jun 30, 2025
TD Securities, Inc.
3.17M
5.79%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.94M
5.36%
+162.06K
+5.84%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.98M
5.44%
+148.82K
+5.26%
Jun 30, 2025
Marshall Wace LLP
2.30M
4.2%
+168.77K
+7.92%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Innovator IBD 50 Fund ETF
4.85%
WisdomTree BioRevolution Fund
2.15%
First Trust Dow Jones Select MicroCap Index Fund
1.79%
Janus Henderson Small Cap Growth Alpha ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
1.43%
Global X Genomics & Biotechnology ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
0.77%
ALPS Medical Breakthroughs ETF
0.73%
iShares Health Innovation Active ETF
0.65%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.64%
查看更多
Innovator IBD 50 Fund ETF
占比4.85%
WisdomTree BioRevolution Fund
占比2.15%
First Trust Dow Jones Select MicroCap Index Fund
占比1.79%
Janus Henderson Small Cap Growth Alpha ETF
占比1.47%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.43%
Global X Genomics & Biotechnology ETF
占比1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
占比0.77%
ALPS Medical Breakthroughs ETF
占比0.73%
iShares Health Innovation Active ETF
占比0.65%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.64%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
